Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Completed 3Terminated 2

Sponsor Class

INDUSTRY 5OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 2Breast 2Genitourinary 1

Conditions

Endometrial Neoplasms 2Breast Neoplasms 2Prostatic Neoplasms 1

Interventions

pembrolizumab 1034Carboplatin 973Paclitaxel 942Gemcitabine 799Cisplatin 759Docetaxel 699Bevacizumab 637Nivolumab 520Pemetrexed 509Cyclophosphamide 476Capecitabine 475Fluorouracil 425Dexamethasone 410Rituximab 392Oxaliplatin 352Injections 349Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 252Ipilimumab 244Doxorubicin 242Lenalidomide 231Fulvestrant 226fludarabine 221durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × irosustat × Clear all
NCT01840488 2019-11-22

BN83495 Phase I in Post-menopausal Women

Ipsen

Phase 1 Completed
50 enrolled
Breast

Breast Neoplasms

NCT00910091 2019-01-30

The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer

Ipsen

Phase 2 Completed
73 enrolled 19 charts
Gynecologic

Endometrial Neoplasms

NCT00790374 2019-01-15

STX64PC

Ipsen

Phase 1 Completed
17 enrolled
Genitourinary

Prostatic Neoplasms

NCT01251354 2019-01-14

Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy

Ipsen

Phase 2 Terminated
6 enrolled 7 charts
Gynecologic

Endometrial Neoplasms

NCT01230970 2019-01-07

Exploratory Study to Assess the Short Term Intratumoural and Peripheral Effects of BN83495 in Postmenopausal Women With Newly Diagnosed Breast Cancer

Ipsen

Phase 2 Terminated
2 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡